# Study of Milciclib in Patients With Unresectable/Metastatic Hepatocellular Carcinoma

> **NCT03109886** · PHASE2 · COMPLETED · sponsor: **Tiziana Life Sciences LTD** · enrollment: 31 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Milciclib maleate

## Key facts

- **NCT ID:** NCT03109886
- **Lead sponsor:** Tiziana Life Sciences LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-12
- **Primary completion:** 2019-05-16
- **Final completion:** 2019-06-20
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2021-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03109886

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03109886, "Study of Milciclib in Patients With Unresectable/Metastatic Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03109886. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*